NOVEL TEST FOR CIRCULATING PROSTATE CANCER CELLS

针对循环前列腺癌细胞的新颖测试

• 批准号: 2643438
• 负责人: PAUL O. P. TS'O
• 金额: $ 10万
• 依托单位: CCC DIAGNOSTICS, LLC
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-09-30 至 1999-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2643438
• 关键词: biomarker; cancer risk; circulating neoplastic cell; diagnosis design /evaluation; diagnostic tests; hormone therapy; human tissue; male; metastasis; neoplasm /cancer chemotherapy; neoplasm /cancer diagnosis; prostate neoplasms

DESCRIPTION: Once cancer is diagnosed in a patient, surgical intervention is common to remove the malignant tumor. There are few clinical tests that can help physicians decide after surgery whether residual cancer cells remain in the body, and more importantly, whether these cells are inconsequential or aggressive and life-threatening. The chance of cancer- free survival of patients with organ-confined prostate cancer can be excellent. A reliable clinical test that indicates whether prostate cancer cells have spread to secondary sites prior to radical prostatectomy will be a valuable tool for the attending physician. The test will help the physician choose the best treatment options for prostate cancer patients. In this application, a novel clinical test that detects, measures quantitatively and characterizes prostate cancer cells circulating in a patients's blood is described. The test is the Works Prostate Cancer Circulating Cell (CC) Test. The investigators seek sufficient data to launch the commercialization and propose to demonstrate a link between circulating cells and prostate cancer risk. In Phase I, the applicants will focus on additional characterizations of the prostate cancer cells in circulation and will verify the effect of already approved chemo/hormonal treatments on the number and characteristics of circulating prostate cancer cells as related to final patient outcome. The objective is to provide the necessary information to determine the individual patient's responsiveness or nonresponsiveness to the specific chemo/hormonal treatment so that the maximum drug efficacy can be obtained for the individual patient based upon the number of circulating prostate cells as an outcome parameter. The applicants propose to use the test as a surrogate response marker in drug development studies as well. PROPOSED COMMERCIAL APPLICATION: Commercial application of this research could be far reaching since the information gained regarding number and characteristics of circulating prostate cancer cells can be useful for the drug company developing drugs, the physician providing therapy and the quality of life for the patient.

描述：一旦患者被诊断出癌症， 是切除恶性肿瘤的常用方法。 几乎没有临床试验 可以帮助医生在手术后决定是否残留癌症， 细胞仍然留在体内，更重要的是，这些细胞是否 无关紧要或具有攻击性并危及生命。 得癌症的几率- 器官局限性前列腺癌患者的自由生存可以 好极了 一个可靠的临床测试，表明前列腺是否 癌细胞在根治性直肠切除术之前已经扩散到第二部位 将是主治医生的宝贵工具。 测试会有帮助的 医生选择前列腺癌的最佳治疗方案 患者在本申请中，一种新的临床试验， 定量测量并表征前列腺癌细胞 描述了在患者血液中循环的。 测试是工程 前列腺癌循环细胞（CC）测试。 调查人员寻求 有足够的数据来启动商业化，并建议证明 循环细胞和前列腺癌风险之间的联系。 在第一阶段， 申请人将集中于前列腺的其它特征 循环中的癌细胞，并将验证已经批准的 化疗/激素治疗对循环系统中 前列腺癌细胞与最终患者结局相关。 客观 是提供必要的信息，以确定个人 患者对特定药物的反应性或无反应性 化疗/激素治疗，以便获得最大的药物疗效 对于个体患者，基于循环前列腺的数量 细胞作为结果参数。 申请人建议将该测试用作 也是药物开发研究中的替代反应标志物。 拟定商业应用： 这项研究的商业应用可能是深远的，因为 获得的关于流通数量和特征的信息 前列腺癌细胞可以用于制药公司开发药物， 医生为患者提供治疗和生活质量。